Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol

Jawsamycin 通过抑制 Spt14/Gpi3 介导的糖基磷脂酰肌醇生物合成,发挥体内抗真菌活性。

阅读:4
作者:Yue Fu # ,David Estoppey # ,Silvio Roggo # ,Dominik Pistorius # ,Florian Fuchs # ,Christian Studer # ,Ashraf S Ibrahim ,Thomas Aust ,Frederic Grandjean ,Manuel Mihalic ,Klaus Memmert ,Vivian Prindle ,Etienne Richard ,Ralph Riedl ,Sven Schuierer ,Eric Weber ,Jürg Hunziker ,Frank Petersen ,Jianshi Tao ,Dominic Hoepfner

Abstract

Biosynthesis of glycosylphosphatidylinositol (GPI) is required for anchoring proteins to the plasma membrane, and is essential for the integrity of the fungal cell wall. Here, we use a reporter gene-based screen in Saccharomyces cerevisiae for the discovery of antifungal inhibitors of GPI-anchoring of proteins, and identify the oligocyclopropyl-containing natural product jawsamycin (FR-900848) as a potent hit. The compound targets the catalytic subunit Spt14 (also referred to as Gpi3) of the fungal UDP-glycosyltransferase, the first step in GPI biosynthesis, with good selectivity over the human functional homolog PIG-A. Jawsamycin displays antifungal activity in vitro against several pathogenic fungi including Mucorales, and in vivo in a mouse model of invasive pulmonary mucormycosis due to Rhyzopus delemar infection. Our results provide a starting point for the development of Spt14 inhibitors for treatment of invasive fungal infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。